Floatz logo

Carboplatin

Ovarian Seromucinous Carcinoma

National Cancer Institute (NCI)Small moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Ovarian Seromucinous Carcinoma cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Carboplatin
National Cancer Institute (NCI)
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB

View all 41 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →